Patents by Inventor Thomas Bruice
Thomas Bruice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070265224Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.Type: ApplicationFiled: June 14, 2007Publication date: November 15, 2007Inventors: Phillip Cook, Guangyi Wang, Thomas Bruice, Nicholas Boyle, Janet Leeds, Jennifer Brooks, Marija Prhavc, Maria Ariza, Patrick Fagan, Yi Jin, Vivek Rajwanshi, Kathleen Tucker
-
Publication number: 20070259832Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.Type: ApplicationFiled: June 14, 2007Publication date: November 8, 2007Inventors: Phillip Cook, Guangyi Wang, Thomas Bruice, Nicholas Boyle, Janet Leeds, Jennifer Brooks, Marija Prhavc, Maria Ariza, Patrick Fagan, Yi Jin, Vivek Rajwanshi, Kathleen Tucker
-
Patent number: 6610663Abstract: Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.Type: GrantFiled: October 10, 2001Date of Patent: August 26, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Thomas Bruice, Charles John Guinosso, Andrew Mamoru Kawasaki, Richard Griffey
-
Publication number: 20020160972Abstract: Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.Type: ApplicationFiled: October 10, 2001Publication date: October 31, 2002Applicant: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Thomas Bruice, Charles John Guinosso, Andrew Mamoru Kawasaki, Richard Griffey
-
Patent number: 6358931Abstract: Compositions and methods for modulating the activity of RNA are disclosed, In accordance with preferred embodiments, antisense compositions are prepared targeting reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.Type: GrantFiled: August 30, 1994Date of Patent: March 19, 2002Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Thomas Bruice, Charles John Guinosso, Andrew Mamoru Kawasaki, Richard Griffey
-
Patent number: 5719271Abstract: Covalent cross-linkages for two oligonucleotide strands or for first and second regions of a single oligonucleotide strand connect sugar moieties of nucleotides on the respective strands or the regions of the single strand. The cross-linkages are connected to at least one strand or region via a space-spanning group. The cross-linkage also can be connected to the other strand or other region via a space-spanning group or via an abasic site located on the other strand or other region.Type: GrantFiled: August 30, 1994Date of Patent: February 17, 1998Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Muthiah Manoharan, Thomas Bruice
-
Patent number: 5543507Abstract: Covalent cross-linkages for two oligonucleotide strands or for first and second regions of a single oligonucleotide strand connect sugar moieties of nucleotides on the respective strands or the regions of the single strand. The cross-linkages are connected to at least one strand or region via a space-spanning group. The cross-linkage also can be connected to the other strand or other region via a space-spanning group or via an abasic site located on the other strand or other region.Type: GrantFiled: March 2, 1994Date of Patent: August 6, 1996Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip D. Cook, Muthiah Manoharan, Thomas Bruice
-
Patent number: 5514786Abstract: Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.Type: GrantFiled: September 10, 1992Date of Patent: May 7, 1996Assignee: Isis Pharmaceuticals, Inc.Inventors: Phillip D. Cook, Thomas Bruice, Charles J. Guinosso, Andrew M. Kawasaki
-
Patent number: 5359051Abstract: Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. In preferred embodiments, the reactive portions comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with and without intervening intercalating moieties and act through phosphorodiester hydrolytic bond cleavage. Therapeutics, diagnostics and research methods are also disclosed. Synthetic nucleosides and nucleoside fragments are also provided which are useful for elaboration of oligonucleotides for such purposes.Type: GrantFiled: March 5, 1992Date of Patent: October 25, 1994Assignee: ISIS PharmaceuticalsInventors: Phillip D. Cook, Charles J. Guinosso, Thomas Bruice